Treatment of acute cerebral artery occlusion using the Penumbra system: our early experience.
Intravenous recombinant tissue-type plasminogen activator (rt-PA) therapy is highly recommended to patients who are diagnosed with ischemic stroke within 4.5 hours after the onset while mechanical clot retrieval can be attempted in patients who are not indicated for or cannot effectively receive intravenous rt-PA therapy. In this article, we report early treatment outcomes and discuss the usefulness of mechanical clot retrieval using the Penumbra system (Penumbra Inc., Alameda, California, USA), especially in terms of technical cautions during the procedure and adaptability to elderly and high National Institutes of Health Stroke Scale (NIHSS) patients. We included 7 patients with thromboembolic occlusion. Pretreatment NIHSS score ranged from 11 to 36 (mean: 24.9). All patients achieved good recanalization [thrombolysis in cerebral infarction (TICI) grade 2a or greater] without complications. The NIHSS score at 30 days after the treatment ranged between 0 and 28 (mean: 12.4), and improved more than 10 points in 4 of the 7 patients (57.1%). To obtain good recanalization without complications, selection of suitable reperfusion catheter and careful manipulation of separator prefiguring the occluded distal vessels are essential. The improved NIHSS score at 30 days after the treatment may have led to favorable results, such as an increased participation in available rehabilitation programs and the alleviation of the burden of care. Our findings suggest that the Penumbra system might be effective for treatment in elderly patients or patients with high NIHSS score wherein rt-PA therapy is inadvisable or ineffective in ischemic stroke secondary to large vessel occlusion. Recanalization can improve their quality of life on condition that the procedure is performed successfully without serious complications.
Department of Neurological Surgery, Kagawa University Faculty of Medicine.
Atsushi
A
Shindo
Masahiko
M
Kawanishi
Kenya
K
Kawakita
Masanobu
M
Okauchi
Nobuyuki
N
Kawai
Naoki
N
Hayashi
Naohiro
N
Osaka
Takashi
T
Tamiya
D000208:Acute Disease; D000368:Aged; D000369:Aged, 80 and over; D001925:Brain Damage, Chronic / Q000453:epidemiology / Q000209:etiology; D057785:Catheters; D002544:Cerebral Infarction / Q000150:complications / Q000534:rehabilitation / Q000601:surgery*; D002986:Clinical Trials as Topic; D000075202:Contraindications; D004867:Equipment Design; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D059906:Neuroimaging; D011788:Quality of Life; D011994:Recombinant Proteins / Q000627:therapeutic use; D015424:Reperfusion; D012189:Retrospective Studies; D016879:Salvage Therapy; D012720:Severity of Illness Index; D013396:Suction / Q000295:instrumentation / Q000379:methods; D017131:Thrombectomy / Q000295:instrumentation* / Q000379:methods; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D016896:Treatment Outcome
D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator